Abstract
Research has shown bidirectional relationships between smoking and adverse sleep behaviours, including late chronotype and insomnia, but the underlying mechanisms are not understood. One potential driver is nicotine, but its role in sleep is unclear. For this study, we estimated the direct effect of nicotine on six sleep behaviours measured in UK Biobank (chronotype, ease of getting up in the morning, insomnia symptoms, napping, daytime sleepiness and sleep duration). We conducted a Mendelian randomisation (MR) study to explore whether nicotine metabolism has a causal effect on these sleep behaviours. We explored whether the effects could be explained by regular nicotine exposure using genetic proxies of the nicotine metabolite ratio (NMR) and cigarettes per day (CPD) in a multivariable MR design. We found a higher NMR (indicating lower levels of circulating nicotine per cigarette smoked) decreased the likelihood of being an evening person when accounting for CPD in current (β = −0.04, 95%CI −0.06 to −0.02, p < 0.001) and ever smokers (β = −0.03 95%CI −0.04 to −0.01, p = 0.003). A higher NMR also increased the ease of getting up (β = 0.02, 95%CI 0.01 to 0.04, p = 0.015) and likelihood of napping (β = 0.02, 95%CI CI 0.002 to 0.03, p = 0.029) in current smokers. Increased nicotine exposure may directly affect sleep and could underlie relationships between smoking and sleep behaviours identified previously. Sleep could also be impacted in individuals using nicotine delivery systems or using nicotine replacement therapies. Further research is warranted to strengthen this conclusion.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded indirectly by the Wellcome Trust (as part of a PhD studentship). The funder played no other role in study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank Resource under Application Number 9142. Further details about the ethics approval sought for data collection in UK Biobank can be found online (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). The authors of the NMR GWAS (Buchwald et al., 2021) provide details of ethics approval for these studies in their paper supplementary materials. The GSCAN GWAS (Liu et al., 2019) received ethics approval from the University of Minnesota Institutional Review Board and all participants provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
